REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Price, Forecast & Analysis
USA - NASDAQ:RDHL - US7574683014 - ADR
RDHL Key Statistics, Chart & Performance
The current stock price of RDHL is 1.16 USD. In the past month the price decreased by -36.61%. In the past year, price decreased by -85.59%.
RDHL Latest News, Press Relases and Analysis
RDHL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.63 | 887.25B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.29B | ||
| MRK | MERCK & CO. INC. | 9.74 | 214.26B | ||
| PFE | PFIZER INC | 7.77 | 141.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.91B | ||
| ZTS | ZOETIS INC | 18.86 | 52.99B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.92 | 23.78B | ||
| VTRS | VIATRIS INC | 4.2 | 11.79B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.42 | 10.69B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.02 | 7.70B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.96B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.10B |
Related stock screener links
About RDHL
Company Profile
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Company Info
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739 IL
CEO: Dror Ben-Asher
Employees: 35
Phone: 97235413131
REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ
What does RDHL do?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Can you provide the latest stock price for REDHILL BIOPHARMA LTD-SP ADR?
The current stock price of RDHL is 1.16 USD. The price increased by 4.5% in the last trading session.
Does REDHILL BIOPHARMA LTD-SP ADR pay dividends?
RDHL does not pay a dividend.
What is the ChartMill rating of REDHILL BIOPHARMA LTD-SP ADR stock?
RDHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RDHL.
What is the employee count for RDHL stock?
REDHILL BIOPHARMA LTD-SP ADR (RDHL) currently has 35 employees.
What is the Short Interest ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
The outstanding short interest for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 358.75% of its float.
RDHL Technical Analysis
RDHL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RDHL. Both the profitability and financial health of RDHL have multiple concerns.
RDHL Financial Highlights
Over the last trailing twelve months RDHL reported a non-GAAP Earnings per Share(EPS) of -2.59. The EPS decreased by -100.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |